Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

  • Lopez-Anglada, L.
  • Cueto-Felgueroso, C.
  • Rosiñol, L.
  • Oriol, A.
  • Teruel, A.I.
  • Lopez de la Guia, A.
  • Bengoechea, E.
  • Palomera, L.
  • de Arriba, F.
  • Hernandez, J.M.
  • Granell, M.
  • Peñalver, F.J.
  • Garcia-Sanz, R.
  • Besalduch, J.
  • Gonzalez, Y.
  • Martinez, R.B.
  • Hernandez, M.T.
  • Gutierrez, N.C.
  • Puerta, P.
  • Valeri, A.
  • Paiva, B.
  • Blade, J.
  • Mateos, M.V.
  • Miguel, J.S.
  • Lahuerta, J.J.
  • Martinez-Lopez, J.
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. Serum samples collected at diagnosis were retrospectively analyzed for sFLC (n = 623) and sHLC (n = 183). After induction or autologous transplantation, 309 and 89 samples respectively were available for sFLC and sHLC assays. At diagnosis, a highly abnormal (HA) sFLC ratio (sFLCr) (<0.03 or >32) was not associated with higher risk of progression. After therapy, persistence of involved-sFLC levels >100 mg/L implied worse survival (overall survival [OS], P = 0.03; progression-free survival [PFS], P = 0.007). Among patients that achieved a complete response, sFLCr normalization did not necessarily indicate a higher quality response. We conducted sHLC investigations for IgG and IgA MM. Absolute sHLC values were correlated with monoclonal protein levels measured with serum protein electrophoresis. At diagnosis, HA-sHLCrs (<0.29 or >73) showed a higher risk of progression (P = 0.006). Additionally, involved-sHLC levels >5 g/L after treatment were associated with shorter survival (OS, P = 0.001; PFS, P = 0.018). The HA-sHLCr could have prognostic value at diagnosis; absolute values of involved-sFLC >100 mg/L and involved-sHLC >5 g/L could have prognostic value after treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma, impact of an MGUS-like signature

  • Rodriguez-Otero, Paula|||0000-0001-5236-7785
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Ocio, Enrique M.|||0000-0002-5765-0085
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Martínez Martínez, Rafael
  • Teruel, Ana Isabel|||0000-0003-1559-7607
  • Gutierrez, Norma|||0000-0001-5834-9510
  • Bargay, Joan|||0000-0002-6739-3916
  • Bengoechea, Enrique
  • González, Yolanda
  • Perez de Oteyza, Jaime|||0000-0002-8338-2037
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Nuñez-Córdoba, Jorge
  • Encinas, Cristina|||0000-0002-9001-9754
  • Martín Sánchez, Jesús|||0000-0003-4250-4824
  • Cabrera-Lopez, Carlos|||0000-0002-6251-4854
  • Palomera, Luis|||0000-0003-0359-7191
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Puig, Noemí|||0000-0001-7535-3861
  • Oriol, Albert|||0000-0001-6804-2221
  • Paiva, Bruno|||0000-0003-1977-3815
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • San Miguel, Jesús F.
Disease control at 5 years would be a desirable endpoint for elderly multiple myeloma (MM) patients, but biomarkers predicting this are not defined. Therefore, to gain further insights in this endpoint, a population of 498 newly diagnosed transplant-ineligible patients enrolled in two Spanish trials (GEM2005MAS65 and GEM2010MAS65), has been analyzed. Among the 435 patients included in this post-hoc study, 18.6% remained alive and progression free after 5 years of treatment initiation. In these patients, overall survival (OS) rate at 10 years was 60.8% as compared with 11.8% for those progressing within the first 5 years. Hemoglobin (Hb) ≥ 12 g/dl (OR 2.74, p = 0.001) and MGUS-like profile (OR 4.18, p = 0.005) were the two baseline variables associated with long-term disease-free survival. Upon including depth of response (and MRD), Hb ≥ 12 g/dl (OR 2.27) and MGUS-like signature (OR 7.48) retained their predictive value along with MRD negativity (OR 5.18). This study shows that despite the use of novel agents, the probability of disease control at 5 years is still restricted to a small fraction (18.6%) of elderly MM patients. Since this endpoint is associated with higher rates of OS, this study provides important information about diagnostic and post-treatment biomarkers helpful in predicting the likelihood of disease control at 5 years.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

  • López-Anglada, Lucía|||0000-0003-1727-8546
  • Cueto-Felgueroso, Cecilia|||0000-0002-4329-9634
  • Rosiñol, Laura|||0000-0002-2534-9239
  • Oriol, Albert|||0000-0001-6804-2221
  • Teruel, Ana Isabel|||0000-0003-1559-7607
  • López de la Guía, Ana|||0000-0002-7705-7844
  • Bengoechea, Enrique
  • Palomera, Luis|||0000-0003-0359-7191
  • De Arriba, Felipe|||0000-0002-4451-1318
  • Hernandez, Jose Mariano
  • Granell, Miquel|||0000-0002-0366-3673
  • Peñalver, Francisco Javier
  • García-Sanz, Ramón|||0000-0003-4120-2787
  • Besalduch, Joan
  • Gonzalez Montes, Yolanda|||0000-0002-4471-5142
  • Martinez, Rafael Benigno
  • Hernández, Miguel Teodoro|||0000-0002-6576-7881
  • Gutierrez, Norma C.
  • Puerta, Paloma
  • Valeri, Antonio
  • Paiva, Bruno|||0000-0003-1977-3815
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Mateos, M. V.|||0000-0003-2390-1218
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Martínez-López, Joaquín|||0000-0001-7908-0063
We investigated the prognostic impact and clinical utility of serum free light chains (sFLC) and serum heavy-light chains (sHLC) in patients with multiple myeloma treated according to the GEM2005MENOS65, GEM2005MAS65, and GEM2010MAS65 PETHEMA/GEM phase III clinical trials. Serum samples collected at diagnosis were retrospectively analyzed for sFLC (n = 623) and sHLC (n = 183). After induction or autologous transplantation, 309 and 89 samples respectively were available for sFLC and sHLC assays. At diagnosis, a highly abnormal (HA) sFLC ratio (sFLCr) (<0.03 or.